SNY
Strong BuyUnloved QualityAI screen passSanofi · Healthcare · France · $99.8B cap · $111.7M/day traded
$39.74 -0.8% · close 12 Oct · scored 14 Oct
StockRank down 2.0 since 13 Oct: Momentum down 3.
Unloved Quality: Strong and cheap; the market has not turned yet.
Read our full research report on SNY (Jun 2026), freeReport expected 30 Oct: the next-year EPS estimate has risen 5.1% over the last 13 weeks.
As of 14 Oct 2026, MoatMap's StockRank for Sanofi (SNY) is 91/100, ranked against 24,000+ stocks in 35 markets (Quality 63, Value 80, Momentum 49, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Passes the eligibility threshold with all three legs (Quality 66, Value 76, Momentum 61) above 60. No adverse in-house signals or negative EPS revisions were identified, supporting a screen-pass.
ABOUT SANOFI
Read
Sanofi is a global biopharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad range of healthcare solutions, encompassing prescription drugs, vaccines, and consumer healthcare products. Its significant competitive moat stems from a highly diversified portfolio of patented drugs and vaccines, strong global R&D capabilities, and extensive commercial reach across multiple therapeutic areas. Sanofi is a leading multinational pharmaceutical firm, particularly prominent in vaccine production and innovation in rare diseases and immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.4B | 46.6B | 49.5B | 52.3B | 4.8% | 54.8B | 56.7B | 60.5B | 7.6% |
| EPS | 3.00 | 2.41 | 2.57 | 3.58 | 6.0% | 1.90 | 3.78 | 4.05 | 6.3% |
| Shares | 1.3B | 1.3B | 1.3B | 1.2B | -4.2% | — | — | — | — |
| Debt | 23.7B | 20.6B | 20.0B | 22.7B | -1.4% | 26.4B | — | — | — |
| Equity | 83.7B | 82.8B | 86.7B | 79.9B | -1.5% | — | — | — | — |
| Op CF | 11.8B | 11.5B | 10.2B | 12.0B | 0.7% | 13.3B | — | — | — |
| Inv CF | -2.3B | -6.9B | -4.9B | -2.7B | — | — | — | — | — |
| Fin CF | -6.5B | -9.0B | -6.4B | -9.2B | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Calmer than 87% of stocks we rank over the past year (22% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SNY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SNY | Sanofi(you) | $99.8B | 91 | Strong Buy |
| G1SK34.SA | GSK plc | $99.9B | 90 | Strong Buy |
| NOVO-B.CO | Novo Nordisk A/S | $169.7B | 92 | Strong Buy |
| PFE.DE | Pfizer Inc. | $159.5B | 89 | Strong Buy |
| BRM.DE | Bristol-Myers Squibb Company | $121.2B | 99 | Strong Buy |
| AMGN | Amgen Inc. | $219.5B | 91 | Strong Buy |
| NOVN.SW | Novartis AG | $271.2B | 91 | Strong Buy |
| 4578.T | Otsuka Holdings Co., Ltd. | $36.6B | 92 | Strong Buy |
| BAYN.DE | Bayer Aktiengesellschaft | $55.2B | 79 | Buy |
| GIS.DE | Gilead Sciences, Inc. | $185.7B | 79 | Buy |
Peer medians: ROE 2.9% · P/E 24.0x · Gross margin 53.8%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.